The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome

被引：0
作者：
Alon Y. Avidan
Daniel Lee
Margaret Park
Mark J. Jaros
Gwendoline Shang
Richard Kim
机构：
[1] Dave Geffen School of Medicine at UCLA,UCLA, Sleep Disorders Center and Department of Neurology
[2] Baptist Health Neurology,undefined
[3] Chicago Sleep Health,undefined
[4] Summit Analytical,undefined
[5] LLC,undefined
[6] XenoPort,undefined
[7] Inc.,undefined
来源：
CNS Drugs | 2016年 / 30卷
关键词：
Rotigotine; Total Mood Disturbance; Gabapentin Enacarbil; Mood Outcome; Mood Analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：305 / 316
页数：11
相关论文
共 8 条
  • [1] Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome
    Lee, Daniel O.
    Buchfuhrer, Mark J.
    Garcia-Borreguero, Diego
    Avidan, Alon Y.
    Ahmed, Mansoor
    Hays, Ryan
    Ondo, William G.
    Jaros, Mark J.
    Kim, Richard
    Shang, Gwendoline
    SLEEP MEDICINE, 2016, 19 : 50 - 56
  • [2] The Effect of Gabapentin Enacarbil on Pain Associated with Moderate-to-Severe Primary Restless Legs Syndrome in Adults: Pooled Analyses from Three Randomized Controlled Trials
    Neal Hermanowicz
    Aaron Ellenbogen
    Gordon Irving
    Mark Buchfuhrer
    Mark J. Jaros
    Gwendoline Shang
    Richard Kim
    CNS Drugs, 2016, 30 : 443 - 454
  • [3] Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil
    Bogan, Richard K.
    Lee, Daniel O.
    Buchfuhrer, Mark J.
    Jaros, Mark J.
    Kim, Richard
    Shang, Gwendoline
    ANNALS OF MEDICINE, 2015, 47 (03) : 269 - 277
  • [4] Effect of Gabapentin Enacarbil on Individual Items of the International Restless Legs Study Group Rating Scale and Post-sleep Questionnaire in Adults with Moderate-to-Severe Primary Restless Legs Syndrome: Pooled Analysis of 3 Randomized Trials
    Ahmed, Mansoor
    Hays, Ryan
    Poceta, J. Steven
    Jaros, Mark J.
    Kim, Richard
    Shang, Gwendoline
    CLINICAL THERAPEUTICS, 2016, 38 (07) : 1726 - 1737
  • [5] Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?
    Kume, Akito
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 249 - 262
  • [6] Dose Response of Gabapentin Enacarbil versus Placebo in Subjects with Moderate-to-Severe Primary Restless Legs SyndromeAn Integrated Analysis of Three 12-Week Studies
    Susan A. Van Meter
    Sarah T. Kavanagh
    Samantha Warren
    Ronald W. Barrett
    CNS Drugs, 2012, 26 : 773 - 780
  • [7] Difference in background factors between responders to gabapentin enacarbil treatment and responders to placebo: pooled analyses of two randomized, double-blind, placebo-controlled studies in Japanese patients with restless legs syndrome
    Inoue, Yuichi
    Hirata, Koichi
    Hoshino, Yuya
    Yamaguchi, Yusuke
    SLEEP MEDICINE, 2021, 85 : 138 - 146
  • [8] Effect of Non-Ergot Dopamine Agonists on Health-Related Quality of Life of Patients with Restless Legs Syndrome
    Talati, Ripple
    Phung, Olivia J.
    Mather, Jeffrey
    Coleman, Craig I.
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (05) : 813 - 821
1